Successful Treatment of Crohn Disease and Concomitant Alopecia Totalis with Upadacitinib: Case Report and Systematic Review of the Literature
DOI:
https://doi.org/10.2340/actadv.v106.adv-2025-0156Keywords:
alopecia areata, alopecia totalis, autoimmune, comorbidity, hair loss, inflammatory bowel disease, JAK inhibitor, small molecule, upadacitinibDownloads
References
Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014; 14: 329–342. DOI: https://doi.org/10.1038/nri3661
Dolinger M, Torres J, Vermeire S. Crohn’s disease. Lancet 2024; 403: 1177–1191. DOI: https://doi.org/10.1016/S0140-6736(23)02586-2
Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 2018; 78: 1–12. DOI: https://doi.org/10.1016/j.jaad.2017.04.1141
O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase Inhibitors in autoimmune diseases. Ann Rheum Dis 2013; 72. DOI: https://doi.org/10.1136/annrheumdis-2012-202576
Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D’Haens G, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with crohn’s disease. Gastroenterology 2020; 158: 2123–2138. DOI: https://doi.org/10.1053/j.gastro.2020.01.047
Levine J, Sharma D, Morsia S, Ungar B. Management of comorbid Crohn’s disease and alopecia universalis with upadacitinib and oral minoxidil. J Dermatolog Treat 2025; 36: 2528704. DOI: https://doi.org/10.1080/09546634.2025.2528704
Johnston LA, Lu C, Poelman SM. Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report. SAGE Open Med Case Rep 2023; 11: 2050313X231160914. DOI: https://doi.org/10.1177/2050313X231160914
Robinson BL, Yoo BS, Lodhia NI. S3886 concurrent management of Crohn’s Ileitis and Alopecia Universalis With Upadacitinib. Am J Gastroenterol 2024; 119: S2536–S2536. DOI: https://doi.org/10.14309/01.ajg.0001044912.80416.c8
Novielli D, Foti C, Principi M, Mortato E, Romita P, Dell’Aquila P, et al. Upadacitinib in concurrent Crohn’s disease, atopic dermatitis and alopecia areata: A case report. Acad Dermatol Venereol 2024; 38. DOI: https://doi.org/10.1111/jdv.19377
Maghfour J, Olson J, Conic RRZ, Mesinkovska NA. The Association between Alopecia and Inflammatory bowel disease: a systematic review and meta-analysis. Dermatology (Basel) 2021; 237: 658–672. DOI: https://doi.org/10.1159/000512747
Perez SM, Kabashima K, Reich K, Gilliet M, Gilhar A, Paus R. Lessons from TNF-α Inhibitor-Induced alopecia areata: Does TNF-α operate as a hair follicle immune privilege guardian under inflammatory conditions? J Invest Dermatol 2025; 145: 2410–2416. DOI: https://doi.org/10.1016/j.jid.2025.04.024
Padda IS, Bhatt R, Patel P. Upadacitinib. Pharma-Kritik ; 41: 45–48.
Stirrat T, Thakker S, Bejugam D, Goh C, Lipner SR. Upadacitinib for alopecia: current evidence and clinical insights. Skin Appendage Disord 2025; 11: 320–334. DOI: https://doi.org/10.1159/000544868
Ferreira C, King B, Torres T. JAK inhibitors for the treatment of vitiligo: current evidence and emerging therapeutic potential. Drugs (Abingdon Engl) 2025; 85: 1521–1534. DOI: https://doi.org/10.1007/s40265-025-02246-1
Ackerman LS, Schlosser BJ, Zhan T, Prajapati VH, Fretzin S, Takahashi H, et al. Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled study. J Am Acad Dermatol 2025; 92: 1252–1260. DOI: https://doi.org/10.1016/j.jaad.2024.12.046
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
